semaglutide death Obesity with established CVD: now indicated to reduce CV death, MI, and stroke Study finds weight loss drug

Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone

While legal, the claim is a bit fishy

Leslie SW, Soon-Sutton TL, Khan MA Male infertility

Health Care Sci

En quienes tienen uremia puede generar debilidad muscular, y convulsiones en quienes padecen de trastornos convulsivos

It is the most common side effect by a wide margin, and it typically follows a predictable pattern